NextCure Statistics
Total Valuation
NextCure has a market cap or net worth of $38.67 million. The enterprise value is -$1.31 million.
Important Dates
The next estimated earnings date is Tuesday, May 19, 2026, after market close.
| Earnings Date | May 19, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NextCure has 3.61 million shares outstanding. The number of shares has increased by 21.97% in one year.
| Current Share Class | 3.61M |
| Shares Outstanding | 3.61M |
| Shares Change (YoY) | +21.97% |
| Shares Change (QoQ) | +48.77% |
| Owned by Insiders (%) | 1.27% |
| Owned by Institutions (%) | 26.75% |
| Float | 2.28M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.94 |
| P/TBV Ratio | 1.01 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.14, with a Debt / Equity ratio of 0.15.
| Current Ratio | 4.14 |
| Quick Ratio | 3.97 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -111.23% and return on invested capital (ROIC) is -64.58%.
| Return on Equity (ROE) | -111.23% |
| Return on Assets (ROA) | -54.96% |
| Return on Invested Capital (ROIC) | -64.58% |
| Return on Capital Employed (ROCE) | -145.43% |
| Weighted Average Cost of Capital (WACC) | 10.58% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.40M |
| Employee Count | 40 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +94.48% in the last 52 weeks. The beta is 1.43, so NextCure's price volatility has been higher than the market average.
| Beta (5Y) | 1.43 |
| 52-Week Price Change | +94.48% |
| 50-Day Moving Average | 11.25 |
| 200-Day Moving Average | 9.70 |
| Relative Strength Index (RSI) | 49.74 |
| Average Volume (20 Days) | 78,313 |
Short Selling Information
The latest short interest is 72,008, so 2.00% of the outstanding shares have been sold short.
| Short Interest | 72,008 |
| Short Previous Month | 55,520 |
| Short % of Shares Out | 2.00% |
| Short % of Float | 3.16% |
| Short Ratio (days to cover) | 1.51 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -57.62M |
| Pretax Income | -55.84M |
| Net Income | -55.84M |
| EBITDA | -55.43M |
| EBIT | -57.62M |
| Earnings Per Share (EPS) | -$19.65 |
Full Income Statement Balance Sheet
The company has $41.82 million in cash and $5.15 million in debt, with a net cash position of $36.67 million or $10.16 per share.
| Cash & Cash Equivalents | 41.82M |
| Total Debt | 5.15M |
| Net Cash | 36.67M |
| Net Cash Per Share | $10.16 |
| Equity (Book Value) | 34.94M |
| Book Value Per Share | 9.97 |
| Working Capital | 33.18M |
Full Balance Sheet Cash Flow
| Operating Cash Flow | -49.61M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 2.19M |
| Net Borrowing | n/a |
| Free Cash Flow | -49.61M |
| FCF Per Share | -$13.75 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NextCure does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -21.97% |
| Shareholder Yield | -21.97% |
| Earnings Yield | -157.96% |
| FCF Yield | -140.33% |
Analyst Forecast
The average price target for NextCure is $23.00, which is 114.55% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $23.00 |
| Price Target Difference | 114.55% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -59.12% |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 14, 2025. It was a reverse split with a ratio of 1:12.
| Last Split Date | Jul 14, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:12 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |